vs

Side-by-side financial comparison of Ginkgo Bioworks Holdings, Inc. (DNA) and Forge Global Holdings, Inc. (FRGE). Click either name above to swap in a different company.

Ginkgo Bioworks Holdings, Inc. is the larger business by last-quarter revenue ($33.4M vs $21.3M, roughly 1.6× Forge Global Holdings, Inc.). On growth, Forge Global Holdings, Inc. posted the faster year-over-year revenue change (10.6% vs -23.8%). Forge Global Holdings, Inc. produced more free cash flow last quarter ($-11.4M vs $-47.7M). Over the past eight quarters, Forge Global Holdings, Inc.'s revenue compounded faster (5.6% CAGR vs -6.2%).

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

Bharat Forge Limited is an Indian multinational company involved in forging, automotives, energy, construction and mining, railways, marine, aerospace and defence industries.

DNA vs FRGE — Head-to-Head

Bigger by revenue
DNA
DNA
1.6× larger
DNA
$33.4M
$21.3M
FRGE
Growing faster (revenue YoY)
FRGE
FRGE
+34.5% gap
FRGE
10.6%
-23.8%
DNA
More free cash flow
FRGE
FRGE
$36.3M more FCF
FRGE
$-11.4M
$-47.7M
DNA
Faster 2-yr revenue CAGR
FRGE
FRGE
Annualised
FRGE
5.6%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
DNA
DNA
FRGE
FRGE
Revenue
$33.4M
$21.3M
Net Profit
$-18.2M
Gross Margin
98.6%
Operating Margin
-211.9%
-96.7%
Net Margin
-85.7%
Revenue YoY
-23.8%
10.6%
Net Profit YoY
0.6%
EPS (diluted)
$-1.41
$-1.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNA
DNA
FRGE
FRGE
Q4 25
$33.4M
Q3 25
$38.8M
$21.3M
Q2 25
$49.6M
$27.7M
Q1 25
$48.3M
$25.3M
Q4 24
$43.8M
$18.6M
Q3 24
$89.0M
$19.2M
Q2 24
$56.2M
$22.3M
Q1 24
$37.9M
$19.2M
Net Profit
DNA
DNA
FRGE
FRGE
Q4 25
Q3 25
$-80.8M
$-18.2M
Q2 25
$-60.3M
$-12.6M
Q1 25
$-91.0M
$-16.2M
Q4 24
$-15.6M
Q3 24
$-56.4M
$-18.3M
Q2 24
$-217.2M
$-13.7M
Q1 24
$-165.9M
$-18.6M
Gross Margin
DNA
DNA
FRGE
FRGE
Q4 25
Q3 25
98.6%
Q2 25
99.4%
Q1 25
99.2%
Q4 24
98.3%
Q3 24
99.6%
Q2 24
98.9%
Q1 24
99.8%
Operating Margin
DNA
DNA
FRGE
FRGE
Q4 25
-211.9%
Q3 25
-231.8%
-96.7%
Q2 25
-132.1%
-46.3%
Q1 25
-184.1%
-65.1%
Q4 24
-236.3%
-100.6%
Q3 24
-62.0%
-108.8%
Q2 24
-396.7%
-79.2%
Q1 24
-469.1%
-130.0%
Net Margin
DNA
DNA
FRGE
FRGE
Q4 25
Q3 25
-207.9%
-85.7%
Q2 25
-121.6%
-45.4%
Q1 25
-188.2%
-63.9%
Q4 24
-84.2%
Q3 24
-63.3%
-95.5%
Q2 24
-386.4%
-61.6%
Q1 24
-437.3%
-96.8%
EPS (diluted)
DNA
DNA
FRGE
FRGE
Q4 25
$-1.41
Q3 25
$-1.45
$-1.37
Q2 25
$-1.10
$-1.01
Q1 25
$-1.68
$-1.29
Q4 24
$-1.91
$3.81
Q3 24
$-1.08
$-1.49
Q2 24
$-4.23
$-1.13
Q1 24
$-3.32
$-1.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNA
DNA
FRGE
FRGE
Cash + ST InvestmentsLiquidity on hand
$422.6M
$60.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$508.6M
$202.6M
Total Assets
$1.1B
$252.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNA
DNA
FRGE
FRGE
Q4 25
$422.6M
Q3 25
$495.5M
$60.7M
Q2 25
$559.4M
$80.7M
Q1 25
$325.3M
$92.0M
Q4 24
$561.6M
$105.1M
Q3 24
$616.2M
$114.5M
Q2 24
$730.4M
$120.5M
Q1 24
$840.4M
$129.6M
Stockholders' Equity
DNA
DNA
FRGE
FRGE
Q4 25
$508.6M
Q3 25
$559.8M
$202.6M
Q2 25
$613.0M
$200.5M
Q1 25
$647.4M
$213.5M
Q4 24
$716.1M
$223.6M
Q3 24
$797.9M
$234.5M
Q2 24
$833.1M
$245.4M
Q1 24
$987.3M
$252.2M
Total Assets
DNA
DNA
FRGE
FRGE
Q4 25
$1.1B
Q3 25
$1.2B
$252.0M
Q2 25
$1.2B
$242.8M
Q1 25
$1.3B
$249.5M
Q4 24
$1.4B
$263.5M
Q3 24
$1.5B
$276.6M
Q2 24
$1.6B
$285.7M
Q1 24
$1.6B
$298.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNA
DNA
FRGE
FRGE
Operating Cash FlowLast quarter
$-47.7M
$-11.4M
Free Cash FlowOCF − Capex
$-47.7M
$-11.4M
FCF MarginFCF / Revenue
-142.8%
-53.6%
Capex IntensityCapex / Revenue
0.0%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-73.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNA
DNA
FRGE
FRGE
Q4 25
$-47.7M
Q3 25
$-31.6M
$-11.4M
Q2 25
$-40.3M
$-7.8M
Q1 25
$-51.5M
$-12.8M
Q4 24
$-42.4M
$-40.5M
Q3 24
$-103.5M
$-5.8M
Q2 24
$-84.4M
$-14.4M
Q1 24
$-89.3M
$-12.4M
Free Cash Flow
DNA
DNA
FRGE
FRGE
Q4 25
$-47.7M
Q3 25
$-11.4M
Q2 25
$-40.3M
$-7.9M
Q1 25
$-59.1M
$-12.9M
Q4 24
$-56.1M
$-41.3M
Q3 24
$-118.6M
$-6.0M
Q2 24
$-111.4M
$-14.7M
Q1 24
$-96.0M
$-12.8M
FCF Margin
DNA
DNA
FRGE
FRGE
Q4 25
-142.8%
Q3 25
-53.6%
Q2 25
-81.2%
-28.4%
Q1 25
-122.4%
-50.9%
Q4 24
-128.0%
-222.3%
Q3 24
-133.2%
-31.0%
Q2 24
-198.2%
-66.0%
Q1 24
-252.9%
-66.4%
Capex Intensity
DNA
DNA
FRGE
FRGE
Q4 25
0.0%
Q3 25
0.0%
0.2%
Q2 25
0.1%
0.4%
Q1 25
15.8%
0.2%
Q4 24
31.3%
4.3%
Q3 24
16.9%
0.7%
Q2 24
48.1%
1.2%
Q1 24
17.7%
2.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

FRGE
FRGE

Marketplace$12.2M57%
Custodial Administration Fees$9.1M43%

Related Comparisons